Antibiotic Drug Market

Key data points: Market size in 2027 = $47.2 billion and 2035 = $57.6 billion, growth forecast = 3.2% annually for the next 8 years. Scroll below to get more insights. This market report covers trends, opportunities and forecasts in antibiotic drug market to 2035 by type (oral, injection, and others), drug (b-lactams, tetracyclines, macrolides, aminoglycosides, peptides, quinolones, and others), application (hospitals, retail pharmacy, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World) Antibiotic Drug Market The future of the global antibiotic drug market looks promising with opportunities in the hospital and retail pharmacy markets. The global antibiotic drug market is expected to reach an estimated $57.6 billion by 2035 from $47.2 billion in 2027 with a CAGR of 3.2% from 2027 to 2035. The major drivers for this market are the increasing prevalence of infectious diseases, the rising resistance to existing antibiotics, and the growing demand for advanced antibiotic treatments. • Lucintel forecasts that, within the type category, injection is expected to witness higher growth over the forecast period due to more immediate results from injectable antibiotic formulations. • Within the application category, hospitals is expected to witness higher growth over the forecast period due to more cases of bacterial infection requiring antibiotic treatment in the hospital. • In terms of regions, APAC is expected to witness the highest growth over the forecast period due to increase in the rate of antibiotic consumption and cases of infectious diseases. Gain valuable insights for your business decisions with our comprehensive 150+ page report. Sample figures with some insights are shown below. Emerging Trends in Antibiotic Drug Market The antibiotic drug marketplace will change in the coming years with a greater emphasis on development of next-generation antibiotics and supplying existing products via more secure and reliable supply routes. Before 2027, health care facilities will choose to procure stewardship-compatible antibiotics. In the meantime, pharmaceutical companies will launch new products with innovative and more broadly-based resistances. Over the next five years, expect a greater investment by the public and private sectors into the development of new antibacterial products. • Addressing Antimicrobial Resistance (AMR): Approximately 16% of bacterial infections reported in 2024 were antibiotic-resistant. In 2025, several policies were enacted to promote development of new antibacterial products. It is anticipated that investment in development of new products will outpace investment in other areas and result in greater availability of products for treatment of resistant infections. • Rising Demand for Molecular Diagnostics and Therapeutics: Novel diagnostics will enable identification of pathogens and resistance markers. With improved diagnostics, the need for empirical prescription of antibacterial drugs will diminish and increase the demand for more targeted products. • Manufacturing Resilience: Following supply disruptions, both the US and EU have employed policies to promote onshore or other supply source diversification of essential medicines and APIs in 2025-2027. As a result, suppliers with manufacturing flexibility across different regions and source transparency will be recognized and rewarded by buyers in the next five years. • Novel Mechanism and Premiumization: Advances in antibacterial and antibiotic research include siderophores and inhibitors of beta-lactamases and other enzymes. Moreover, microbiota-and-mycobiota-targeted therapies are under development. While funding for anti-infective research has been inadequate, pharmaceutical companies have raised prices for established antibiotics to compensate for diminishing sales. • Stewardship-linked Access Models: The decoupling of medical prescription and reimbursement will facilitate the financial viability of stewardship for reserve antibiotic strategies. There is growing commercialization of antibiotic stewardship programs. The clinical efficacy and resistance profile of a supplier take precedence over prescription volume. Continuous investment will be challenged by pricing and reimbursement certainty. The production of antibiotics and other anti-infectives will be more lucrative if supply is coupled with diagnostics, and the public sector takes a larger role. Supply chain resilience and stewardship will foster reputation and leadership in the market. Recent Developments in the Antibiotic Drug Market Antibiotic drug market activity is expected to increase from 2025 to 2027. During this time, Lucas Consulting Group, Inc. (Lucintel) believes that resistance will lead to increased hospital-level demand, and regulatory authorities will allow the marketing of antibiotics based on new, novel mechanisms of action. Lucintel expects that the main strategies employed by market participants during this time will be the commercialization of high-value, antibiotic-based therapies and the implementation of risk-pooling and prize-based funding structures. Until reimbursement-related challenges are addressed, the commercialization of high-value, antibiotic-based therapies is expected to remain challenging. • Regulatory Approval of Novel Oral Antibiotics: Over the last few years, U.S. regulatory authorities have permitted the marketing of several new oral antibiotics. GSK’s Blujepa (gepotidacin) was approved in March 2025 for the treatment of uncomplicated urinary tract infections. Given the constraints of antimicrobial stewardship, it is expected that new, differentiated antibiotic therapies will be commercially successful in premium-positioned markets. • Hospital Focused Product Expansion: Pfizer’s Emblaveo (aztreonam-avibactam) was also approved in February 2025 to treat complicated intra-abdominal infections. Like other new, premium-priced, broad-spectrum reserve antibiotics, it is expected that Emblaveo will be positioned in the hospital market, and resistance-adjusted clinical value will determine price. • Public Funding for Antimicrobial Innovation: CARB-X anticipates providing more than $500 million for early stage antibacterial projects by 2025, including funding from public and private sources. Private equity is unwilling to fund projects to develop new antibiotics, as the return on investment is too long and uncertain. The Gates Foundation believes that the development of new antibiotics will require public-private partnerships. • Public-Public Partnerships: Recent transactions by Innoviva illustrate the growing trend to utilize strategic alliances and partnerships to obtain late stage and marketed anti-infectives. These alliances offer the potential to acquire new products more quickly and to gain control of a given product in a given market. • Linked Products: As of 2025, many health care facilities integrated rapid (molecular) diagnostic testing and antimicrobial stewardship. By that time, many health care facilities adopted a strategy of using rapid diagnostics to inform anti-infective therapy. Between 2025 and 2027, several novel antibiotics are expected to be approved for marketing. The improvement in treatment for infections is expected to be more economical and improve treatment outcomes. Public health systems should implement novel antibiotics, but affordable, rapid diagnostics are also needed to improve treatment outcomes. Public financing, in the form of subscriptions, should also be directed towards the development of improved diagnostics and antibiotics. Strategic Growth Opportunities in the Antibiotic Drug Market From 2024-2026, the antibiotic market will focus on innovation for resistance and hospital-based stewardship. There will also be shifts to access-based models. Meanwhile, changes to diagnostics and procurement will improve the market outlook for antibiotics. Lucintel expects that the market for traditional broad-spectrum antibiotics will remain stable. • Novel Agents for Resistant Infections: Premium antibiotics will be innovated to treat carbapenem-resistant infections. In 2025, the World Health Organization (WHO) listed 15 carbapenem-resistant infections in the priority list of resistant infections. Other inhibitors for drug-resistant Gram-negative infections may also be innovated. • Rapid Diagnostics-linked Therapy: Rapid diagnostics that inform antimicrobial susceptibility will enhance prescribing and promote stewardship. Furthermore, many diagnostics will be reimbursed by third-party payers, especially in the next 3 to 5 years. Integrating diagnostics with prescribing will encourage the use of the right antibiotic and lower resistance. • Outpatient Formulations: Antibiotics in long-lasting, easy-to-use outpatient formulations are becoming more widespread. The US recently built up its outpatient infrastructure to the point that in 2025 it recorded 35 million outpatient visits. Longer-lasting antibiotics provide greater convenience and reduce costs, therefore the market is likely to shift to better and more expensive outpatient antibiotics. • Livestock and Fish Farming: The demand for foods increases and with it the need for farming. Increased farming requires improved strategies to maintain the health of livestock and fish, and to help livestock and fish farming be more productive. Improved farming will help satisfy the increased global demand for food. 2025 saw the need for a 50% increase in food production to support the world’s growing population. • Sustainable Manufacturing: Manufacturing requires a lot of energy. Pharmaceutical companies are trying to reduce their carbon footprint and find more sustainable ways of producing pharmaceuticals. The manufacturing company that is able to guarantee the least impact on the environment will have a competitive edge. There will also be improved contracts awarded to more sustainable companies. Pharmaceutical companies will need to increase their number of antibiotics to survive. Just having new antibiotics will not be enough to increase profits. Additionally, companies will need to improve diagnostics, increase outpatient delivery, and focus on the veterinary market in order to survive. Also, companies will need to improve manufacturing to ensure that they meet the strain of increasing demand while sustaining the environment. Companies will need to strategically price their products. It will be important for companies to focus on the areas with the greatest need and improving company contracts. Antibiotic Drug Market Drivers and Challenges The market is growing because of increasing rates of infection, more resistant infections, more research, more spending by the biopharma companies and more advanced regulation. There is growing demand and stewardship to decrease the use of antibiotic drugs. Other factors affecting the market are the cost of production and the flexibility of the supply, how much the drug pays, the complexity of clinical trials, and level of competition. According to Lucintel, the market is futuristic and depend on trade-offs between the cost and accessibility of the drugs, how safe the drugs are, and how responsible the companies are in selling the drugs in the market. The factors responsible for driving this market include: • More Cases of Infectious Diseases: Increased travel, population growth and density, and increased healthcare facility use have all increased rates of antibiotic-susceptible infections. Immunocompromised patients, like the very young, the very old, and patients with cancer and diabetes, are at increased risk for invasive bacterial infections. In March 2025, the U.S. Food and Drug Administration (FDA) approved geopolitician for the treatment of uncomplicated urinary tract infections. It is anticipated that in the next 3-5 years, increased diagnostic efforts and infection rates will result in greater antibiotic use, particularly in the outpatient setting and in developing countries. • Innovation in Antibiotics and The Market Gap: The impact of antibiotic resistance is increasing and is leading to a reliance on combination and last-resort antibiotics. Healthcare practitioners are especially eager for alternatives to the limited options available to treat antibiotic-resistant infections, particularly in critically-infected and intensive care patients. In April 2025, the World Health Organization (WHO) confirmed that advances in antibiotic resistance heighten threats to global public health, and reinforced the need for new and existing antibiotic technologies and policies. In this environment, the next three to five years will likely reward the development of novel, antibiotic combinations and stewardship will generally dictate that such combinations be used judiciously. • Research and Development in New Antibiotics: Traditionally, research and development of new antibiotics has relied on the discovery of new chemical entities. Other avenues that are more speculative and science fiction are receiving renewed interest and funding. Examples include antimicrobial peptides and bacteriophages. The emergence of Artificial Intelligence and other computer-based technologies and recent Genomic advances are also expected to facilitate the discovery and commercialization of new antibiotics. The U.S. Food and Drug Administration (FDA) approval of geopolitician in March 2025 is further evidence of a renaissance in commercial antibiotic research and development. • Regulatory and Economic Incentives: Varied legislation to incentivize investment in antibiotic development to address market failure continues to grow. Examples of such legislation include grants, priority reviews, and subscription models. While these policies reduce the risk of investing in limited market antibiotic products, they do not ultimately address the underlying issue of enhancing the commercial attractiveness of the antibiotic market. In September 2025, the United Kingdom opted to renew its subscription model for antibiotic procurement. It is expected that public-private financing and other innovative policies to enhance the antibiotic development pipeline will improve the pipeline of antibiotics to address multidrug resistant infections within the next 3 to 5 years. • Healthcare Infrastructure and Manufacturing: More robust healthcare and pharmaceutical manufacturing infrastructures in various countries have improved the reliability of antibiotic supply. Improving manufacturing infrastructure and active pharmaceutical ingredient supply chain diversity will further reduce antimicrobial drug shortages. In January 2025, Production Linked Incentive schemes for the Indian pharmaceutical industry were extended by the Government of India. It is expected that similar policymaking to strengthen manufacturing, distribution and pharmacy infrastructure will improve the reliability of the supply of quality medicines. The challenges facing this market include: • Antimicrobial Resistance and Stewardship: Resistant infections create a medical emergency, but can also curtail and restrict antibiotic use. For example, public health and pharmaceutical stewardship can result in a hospital or health system formulary restriction or prohibition of the use of a particular antibiotic. These policies and restrictions can negatively impact commercial potential of a product and complicate returns on investment (ROI), especially if a product is reserved for only the most serious infections. In April 2025, the World Health Organization (WHO) stated that there are more than one million deaths each year from resistant bacterial infections. They also noted that these infections are unacceptably high and continue to rise. Resistant infections are expected to increase and create further public health demand for advanced and novel products and therapies. However, stewardship programs and restriction on routine clinical use will remain. Therefore, to demonstrate and support the clinical need for products in this market, companies will need to develop sustainable access models. • High Development Costs and Low Market Potential: While the science and research surrounding novel antibiotics is intensive and advanced, the reimbursement and market potential is highly uncertain and unpredictable. Like all other pharmaceuticals, antibiotics also face public health policy restraints regarding product use and restriction. In March 2025, the U.S. Food and Drug Administration (FDA) approved geopolitician for the treatment of urinary tract infections, despite potential public health restriction regarding overuse of the product. High development costs, small market potential, and public health policy restraints will challenge antibiotic development in the next 3 to 5 years, especially for small biopharmaceutical companies. • Supply-chain Challenges and Price and Quality Pressures: The active pharmaceutical ingredients (APIs) for antibiotics are subject to supply shortages and price volatility. The industry is also subject to price competition and strict requirements on quality and purity. Concentrated production increases reliance on supply routes, which are subject to disruptions. In October 2025, the international organizations focused on public health indicated that rebalancing the global pharmaceutical supply chains was essential to address the global shortages of medicines. In the next three to five years, public and private efforts to strengthen regional supply chains are expected to increase, but the additional costs may increase prices and increase competition. The increasing incidences of cross-border infectious diseases, pathogenic resistance, and the expansion of the global healthcare system are expected to increase the demand for antibiotics. Investments in the manufacturing of antibiotics may be encouraged by new priorities and policies of regulatory agencies. Additionally, stewardship programs and other public health policies may promote the responsible use of antibiotics. The ability to strike a balance among the aforementioned factors may determine the long-term success of a company in the antibiotics market. It is expected that in the next three to five years, improvements to the resilience of the healthcare systems and more effective innovation would be prioritized over greater access and higher market shares of antibiotics. List of Antibiotic Drug Market Companies Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies antibiotic drug market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the antibiotic drug market companies profiled in this report include- • GSK • Pfizer • Merck & Co • Sandoz • Sumitomo Pharma • Fresenius • AbbVie • Hailin Pharmaceuticals • Bausch Health • Southwest Pharmaceuticals Antibiotic Drug Market by Segment The study includes a forecast for the global antibiotic drug market by type, drug, application, and region. Antibiotic Drug Market by Type [Value ($B) from 2019 to 2035]: • Oral • Injection • Others Antibiotic Drug Market by Drug [Value ($B) from 2019 to 2035]: • B-lactams • Tetracyclines • Macrolides • Aminoglycosides • Peptides • Quinolones • Others Antibiotic Drug Market by Application [Value ($B) from 2019 to 2035]: • Hospitals • Retail Pharmacy • Others Antibiotic Drug Market by Region [Value ($B) from 2019 to 2035]: • North America • Europe • Asia Pacific • The Rest of the World Country Wise Outlook for the Antibiotic Drug Market New government policies will play a significant role in shaping the global antibiotic drug market between 2025 and 2027. During this period, various government agencies will establish reliable mechanisms for the procurement of existing and new antibiotic drugs. New policies and programs aimed at combatting antimicrobial resistance will direct and encourage new investments in the manufacture of antibiotic drugs. According to Lucintel, policies will influence commercial strategies; however, the effects will be felt at the national level. • United States: New policies to promote and stimulate research in the area of antibacterial drugs will be implemented in the near future. Once these policies take effect, it is expected that a considerable number of companies will dedicate their resources towards research and development in antibacterial drugs, thus creating a market for new classes of antibacterial drugs. • China: Although there has not been much progress in combating antimicrobial resistance in China, the framework and strategies put in place will promote advancements and innovations in anti-infective drugs. Unlike several years ago, it is likely that newer anti-infective drugs will be produced and marketed in China in the near future. • Germany: In 2025, the German Federal Ministry of Health promoted various activities to prevent and control antimicrobial resistance, including the implementation of the national strategy to combat antimicrobial resistance. About 100 actions have been designed to address the strategy. The actions cover the field of antimicrobial resistance in a comprehensive manner, including the optimization of the surveillance and the stewardship and infection control activities across health care facilities. In a growing economy with a robust health care sector, ongoing efforts to balance and align antibiotic resistance, diagnostics, and related supplies are expected. • India: The Indian Department of Pharmaceuticals gave another year of financial support (2025) to local companies to manufacture and re-manufacture 41 critical pharmaceutical ingredients, including antibiotics, through its “Production Linked Incentive” scheme. Public health and other relevant sector coordination should maximize the local manufacture of antibiotics in the short to medium term (3-5 years) and ensure health infrastructure related to the production of antibiotics remains in India. • Japan: Japan also extended (for another year) its national plan to 2027 to promote research and help strengthen systems to address antimicrobial resistance. Strong public health and sectoral coordination should continue to address antibiotic resistance. Features of the Global Antibiotic Drug Market Market Size Estimates: antibiotic drug market size estimation in terms of value ($B). Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions. Segmentation Analysis: antibiotic drug market size by type, drug, application, and region in terms of value ($B). Regional Analysis: antibiotic drug market breakdown by North America, Europe, Asia Pacific, and Rest of the World. Growth Opportunities: Analysis of growth opportunities in different types, drugs, applications, and regions for the antibiotic drug market. Strategic Analysis: This includes M&A, new product development, and competitive landscape of the antibiotic drug market. Analysis of competitive intensity of the industry based on Porter’s Five Forces model. If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more. This report answers following 11 key questions: Q.1. What are some of the most promising, high-growth opportunities for the antibiotic drug market by type (oral, injection, and others), drug (b-lactams, tetracyclines, macrolides, aminoglycosides, peptides, quinolones, and others), application (hospitals, retail pharmacy, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)? Q.2. Which segments will grow at a faster pace and why? Q.3. Which region will grow at a faster pace and why? Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market? Q.5. What are the business risks and competitive threats in this market? Q.6. What are the emerging trends in this market and the reasons behind them? Q.7. What are some of the changing demands of customers in the market? Q.8. What are the new developments in the market? Which companies are leading these developments? Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth? Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution? Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?